White & Case advises Merck KGaA on acquisition of Erbi Biosystems
Global law firm White & Case LLP has advised Merck KGaA, Darmstadt, Germany (Merck), a leading science and technology company, on its acquisition of Erbi Biosystems, the developer of the Breez 2-ml microbioreactor technology platform.
The acquisition of US-based Erbi Biosystems strengthens Merck’s portfolio of therapeutic proteins and creates future development opportunities, including in the area of cell therapies. The transaction is part of the company’s strategy to accelerate innovation through targeted acquisitions of small- to mid-sized high impact companies.
The parties have agreed not to disclose financial details. The acquisition was completed on December 1, 2022.
Merck KGaA, headquartered in Darmstadt, Germany, is a leading science and technology company active in the healthcare, life science and electronics sectors. The company employs approximately 60,000 people and in 2021 generated sales of €19.7 billion in 66 countries.
US-based Erbi Biosystems maintains a research and development and manufacturing in Massachusetts. Its products are used in the US, Europe and China.
The White & Case team which advised on the transaction was led by partner Stefan Koch (Frankfurt) and included partner Victoria Rosamond (New York), counsel Samantha Rozell (Chicago) and associates Caitlin Powell Gimpel (Milan), Christian Sperling (Frankfurt) and Tyrone Crawford (Washington, DC).